Navigation Links
Generex Announces Publication of New Positive Generex Oral-lyn™ Data in Peer-Reviewed Journal
Date:12/13/2010

WORCESTER, Mass., Dec. 13, 2010 /PRNewswire/ -- Generex Biotechnology Corporation (www.generex.com) (OTC Bulletin Board: GNBT) announced today that the peer-reviewed scientific journal Diabetes, Obesity and Metabolism has published new positive data in respect of Generex Oral-lyn™, the Company's proprietary buccal insulin spray product.

The paper, entitled Buccal spray insulin in subjects with impaired glucose tolerance: the prevoral study, appears in Volume 13, Issue 1 (January 2011) of the journal and is co-authored by a team from the Department of Endocrinology and Diabetes, University Campus Bio-Medico, Rome, Italy led by Professor Paolo Pozzilli and including: A. Palermo, N. Napoli, S. Manfrini, A. Lauria, and R. Strollo.

People affected by impaired glucose tolerance (IGT) represent more than 20% of the world's population and the prevalence of the condition is growing.  Approximately one-third of people with IGT develop clinical type 2 diabetes mellitus within three to five years of an IGT diagnosis.  More significantly, an increased risk for cardiovascular disease has been observed in IGT patients, even where type 2 diabetes does not develop.  Although diet and exercise (the treatment for IGT suggested by current American Diabetes Association guidelines) delay the onset of type 2 diabetes, long-term prospects are poor.

Because a reduced first phase insulin response is a key factor in diagnosing IGT, the use of insulin therapy to reduce post-prandial glucose levels could be a targeted treatment for IGT.  However, insulin therapy via subcutaneous injection is often rejected by patients and its use is generally limited to patients with type 2 diabetes where oral hypoglycaemic options have failed.

In Professor Pozzilli's proof-of-concept study, 31 subjects diagnosed with IGT,
'/>"/>

SOURCE Generex Biotechnology Corporation
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Generex Biotechnology Corporation Initiation Coverage Review Issued By Scimitar Equity, LLC
2. Generex Announces Distribution Agreement for Generex Oral-lyn™ in Chile
3. Generex Announces Presentations of Novel Vaccine Strategies
4. Generex Announces Approval of Adjournment Proposal and Adjourned Special Meeting Date
5. Generex Announces Sales Agreement with Elias Shaker & Company
6. Generex Presents Abstract at EASD Annual Meeting
7. Generex Awarded a New Patent in Canada for its Proprietary Buccal Drug Delivery System
8. Generex Biotechnology Provides a Corporate Update to Address Managements Strategic Initiatives for Growth
9. Generex Reaches Agreement to Acquire 51% Stake in Global Medical Direct, a Nationwide Durable Medical Equipment and Pharmaceutical Provider Specializing in Direct-to-Consumer Diabetes Supplies
10. Generex Provides Clarification for Special Meeting Voting
11. Generex Announces That Adjournment Will be Sole Matter Considered at Reconvened Special Meeting of Stockholders on October 15, 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... CHINA , May 24, 2013 ... or the "Company"), a leading China ... manufacturing and marketing biopharmaceutical products, announced today that, ... "EGM"), the Company,s shareholders voted in favor of ... announced agreement and plan of merger dated February ...
(Date:5/23/2013)...  Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA ) ... Life Science Firm of the Year by the Tech Council ... at the TCM,s 25 th Annual Tech Awards Celebration ... Awards Celebration recognizes the leaders and innovators in the technology ... and the surrounding regions. "We are deeply ...
(Date:5/23/2013)... y PARÍS, 24 de mayo de ... ), un destacado desarrollador y fabricante de herramientas ... la diagnosis y tratamiento de la enfermedad vascular ... del ensayo ADVISE ( Ad enosine V ... E valuation) II durante la sesión de ensayo ...
Breaking Medicine Technology:3SBio Inc. Announces Shareholders' Approval of the Amended Merger Agreement 23SBio Inc. Announces Shareholders' Approval of the Amended Merger Agreement 3Vanda Pharmaceuticals Named the 2013 Life Science Firm of the Year by the Tech Council of Maryland 2Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 2Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 3Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 4Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 5Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 6
... Horror stories related to medical equipment for new construction or ... of dollars are wasted, and delays in go-live dates can ... an independent nonprofit that researches the best approaches to improving ... 6 best practices to ensure a better outcome in a ...
... Oct. 28 DUSA Pharmaceuticals, Inc.® (Nasdaq GM: ... announced today that global sales volumes of the ... Photodynamic Therapy (PDT) technology platform, surpassed one million ... that dermatologists in the U.S. and abroad continue ...
Cached Medicine Technology:Is Poor Medical Equipment Planning Costing your Healthcare Project Wasted Dollars and Delays? ECRI Institute outlines best practices to ensure better outcomes 2Is Poor Medical Equipment Planning Costing your Healthcare Project Wasted Dollars and Delays? ECRI Institute outlines best practices to ensure better outcomes 3DUSA Pharmaceuticals Surpasses One Million in Cumulative Levulan(R) Kerastick(R) Sales Units 2
(Date:5/23/2013)... By Denise Mann HealthDay Reporter , , THURSDAY, ... of Americans take to help treat hip and knee ... increase risk for developing glaucoma, a small new study ... there is an increase of intraocular pressure (IOP) or ... of the leading causes of blindness. ...
(Date:5/23/2013)... 2013 Memorial Day Focus Spotlight on ... been a part of the U.S. Military for more ... preceding it, these men and women will be honored ... of America. As veterans transition to civilian life, ... the workplace chaplaincy world. , Marketplace Chaplains, America’s ...
(Date:5/23/2013)... “Talk. They Hear You.” a new national ... talk to children as young as nine years old ... by the Substance Abuse and Mental Health Services Administration ... SAMHSA’s 2013 National Prevention Week—an annual health observance dedicated ... and mental health issues. , SAMHSA’s latest report on ...
(Date:5/23/2013)... to its destruction inside a cell, a cancer-promoting ... thwart the development of tumor-suppressing microRNAs (miRNAs) before ... publication at Nature . , Under conditions ... epidermal growth factor receptor (EGFR) gums up the ... scientists at The University of Texas MD Anderson ...
(Date:5/23/2013)... carries a poor prognosis, with limited treatment options. ... the way it,s supposed to. New research from Western ... chemotherapy, and identifies a mechanism to rectify that. ... and his team at Western,s Schulich School of Medicine ... to promote the death of cancer cells by binding ...
Breaking Medicine News(10 mins):Health News:Glucosamine Supplements Tied to Risk of Eye Condition 2Health News:Glucosamine Supplements Tied to Risk of Eye Condition 3Health News:Memorial Day Focus Spotlight on Military Chaplains Transitioning in the Marketplace 2Health News:Memorial Day Focus Spotlight on Military Chaplains Transitioning in the Marketplace 3Health News:New Campaign to Help Parents Talk to Younger Children About the Dangers of Underage Drinking 2Health News:When oxygen is short, EGFR prevents maturation of cancer-fighting miRNAs 2Health News:When oxygen is short, EGFR prevents maturation of cancer-fighting miRNAs 3
... have arisen about the best approach whether it is public ... that more people want public services offering better health care ... Queen Elizabeth Hospital is an example financial difficulty due to ... study reveals that the health care provided by the not-for-profit ...
... a well-known fact that nearly 1/3rd of our lifetime is ... important as the quantity. People who have odd working hours ... chronic sleep deprivation that is responsible for fatigue and other ... North Polar Region have for the first time shed light ...
... the University of Washington researchers between obesity and asthma. ... the Journal of Allergy and Clinical Immunology. Previous studies ... develop asthma. The new research reveals the common genetic ... ,The researchers led by Dr. Teal Hallstrand analyzed ...
... French are reluctant to place their orders for Christmas turkeys ... ,However, the dreaded disease has not stopped the British and ... year, say industry sources. ,In France, bulk ... orders, say industry sources. The consumer confidence seems to have ...
... on bird shows in Britain has been lifted on account of ... ,Various events such as pigeon racing, falconry and other bird shows ... bird flu scare in October which was detected in Eastern Europe ... now since no single case of bird flu was reported the ...
... regarding the Christmas dinner. Turkey still remains popular inspite of the ... risen by 25% in Britain. Supermarket owners say that the sales ... ,When bird flu was spreading and was in its peak ... sales will fall very sharply. ,But the health officials ...
Cached Medicine News:Health News:Reindeer Provide Valuable Insights Into Sleep Disorders 2Health News:Christmas turkey? Anyone? 2
... KeraCel Ophthalmic Products are constructed ... of lint-free MEROCEL polyvinyl acetal ... to be beneficial to both ... absorbent, and yet firm enough ...
... KeraCel Ophthalmic Products are constructed ... of lint-free MEROCEL polyvinyl acetal ... to be beneficial to both ... absorbent, and yet firm enough ...
...
... Merocel Ophthalmic Products ... superior fiber free products ... and safe cleaning of ... exclusive Merocel material is ...
Medicine Products: